Mithramycin

WikiDoc Resources for Mithramycin
Articles
Most recent articles on Mithramycin Most cited articles on Mithramycin Review articles on Mithramycin Articles on Mithramycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mithramycin Images of Mithramycin Photos of Mithramycin Podcasts & MP3s on Mithramycin Videos on Mithramycin
Evidence Based Medicine
Cochrane Collaboration on Mithramycin Bandolier on Mithramycin TRIP on Mithramycin
Clinical Trials
Ongoing Trials on Mithramycin at Clinical Trials.gov Trial results on Mithramycin Clinical Trials on Mithramycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mithramycin NICE Guidance on Mithramycin NHS PRODIGY Guidance FDA on Mithramycin CDC on Mithramycin
Books
Books on Mithramycin
News
Mithramycin in the news Be alerted to news on Mithramycin News trends on Mithramycin
Commentary
Blogs on Mithramycin
Definitions
Definitions of Mithramycin
Patient Resources / Community
Patient resources on Mithramycin Discussion groups on Mithramycin Patient Handouts on Mithramycin Directions to Hospitals Treating Mithramycin Risk calculators and risk factors for Mithramycin
Healthcare Provider Resources
Symptoms of Mithramycin Causes & Risk Factors for Mithramycin Diagnostic studies for Mithramycin Treatment of Mithramycin
Continuing Medical Education (CME)
CME Programs on Mithramycin
International
Mithramycin en Espanol Mithramycin en Francais
Business
Mithramycin in the Marketplace Patents on Mithramycin
Experimental / Informatics
List of terms related to Mithramycin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Mithramycin is an anti-neoplastic antibiotic. Its major use is as an IV infusion to reduce very high levels of plasma calcium. It inhibits RNA synthesis in osteoclasts. Typically use a dose of 25 microgram per kilogram IV given over four to six hours. This dose can be repeated in 1 to 2 days if necessary. Ca⁺⁺ levels start falling after 12 hours, with maximal reduction at 48-72 hours.

Hypercalcaemia recurs in days to several weeks. With repeated use, organotoxicity (kidney, liver, haematopoetic system) can become a problem.